zed1227
Small moleculeexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Apr 19, 2022 (NCT05305599)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
TGM2 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07298343 | Phase 2 | Jun 10, 2024 | Dr. Falk Pharma GmbH, Takeda |
| NCT05305599 | Phase 2 | Apr 19, 2022 | Dr. Falk Pharma GmbH |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Dr. Falk Pharma GmbH | For profit | 2 | 2 | 1 | 2022 |
| Takeda | For profit | 1 | 0 | 1 | 2024 |
2 organizations
Page 1 / 1